Navigation Links
Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials

NEW YORK, Feb. 4, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced its OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials (180 patients per clinical trial) being conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers.

The Company anticipates completing these trials in the second half of 2016 and is targeting a New Drug Application (NDA) submission with the U.S. Food and Drug Administration in the first half of 2017 and a Marketing Authorization Application (MAA) submission with the European Medicines Agency in the second half of 2017. More information about the OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials is available at<>.

About Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of Dipexium Pharmaceuticals, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submission for Locilex®) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Company Contacts:

David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.

David Garrett
Vice President, Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.

© 2016 Dipexium Pharmaceuticals, Inc.  All rights reserved.

SOURCE Dipexium Pharmaceuticals, Inc.
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Dipexium Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
2. Dipexium Pharmaceuticals Reports Third Quarter 2014 Financial and Operational Results
3. Dipexium Pharmaceuticals to Present at Jefferies 2015 Antibiotic Summit
4. Dipexium Pharmaceuticals to Hold Year End 2014 Financial Results Conference Call on Tuesday, March 24, 2015, 8:30 a.m. ET
5. Dipexium Pharmaceuticals Reports 2014 Financial Results
6. Dipexium Pharmaceuticals to Hold First Quarter 2015 Financial Results Conference Call on Thursday, May 14, 2015, at 8:30 a.m. ET
7. Dipexium Pharmaceuticals Reports First Quarter 2015 Financial Results
8. Dipexium Announces Presentation at 7th International Symposium on the Diabetic Foot
9. Dipexium annonce une présentation lors du 7e International Symposium on the Diabetic Foot
10. Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an
11. Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético
Post Your Comments:
(Date:11/8/2018)... ... November 08, 2018 , ... ... facilities specifically for bariatric patients with addiction or mental health disorders. This ... sleeve procedures. , D’Amore Healthcare’s Whole Person™ Bariatric Addiction Recovery Program treats ...
(Date:11/8/2018)... ... November 08, 2018 , ... Implant Direct and ... Implant Direct will provide dental implants to Heartland Dental, the nation’s largest dental ... than 875 offices in 37 states. , “We are thrilled to partner ...
(Date:11/8/2018)... ... November 08, 2018 , ... CLYNK (Count and Crush, LLC), a national leader in ... Townsquare Media, Inc. , launched the Cans for a Cure charity bottle drive over ... $100,068.06 for the Dempsey Center to help families impacted by cancer. Over $12,749 ...
Breaking Medicine Technology:
(Date:11/8/2018)... ... 2018 , ... On the 16th of November 1898, in ... Hysterectomy. On the 12th of November 2018, in Las Vegas, Nevada, the AAGL ... surgical procedure at the opening session of the 47th Annual AAGL Global Congress ...
(Date:11/7/2018)... ... November 07, 2018 , ... AccentCare, managed by Veteran leadership, is proud to ... “We thank Veterans everywhere for ensuring our freedom and are humbled every day by ... AccentCare CEO Steve Rodgers, who was a Special Forces Medic in the U.S. Army. ...
(Date:11/7/2018)... ... November 07, 2018 , ... EmbraceRace was chosen ... earlier this year. Their work and that of other select changemakers will be ... , The Erase The Hate accelerator program honors organizations committed to countering hate ...
(Date:11/7/2018)... ... November 07, 2018 , ... ... many benefits of human growth hormone (HGH) replacement therapy, for men and women ... say that for various reasons, many patients have reservations about taking HGH, and ...
(Date:11/7/2018)... ... 07, 2018 , ... Medrio, the leading provider of eClinical ... 2018 DIA Japan Annual Meeting in Tokyo. Representatives from the company, including founder ... 13 to discuss clinical research and technology with attendees. Medrio product specialists will ...
Breaking Medicine News(10 mins):